
Patients with ESR1 mutations who received 12 months or more of prior treatment with a CDK4/6 inhibitor achieved a median progression free survival of 8.61 months with elacestrant compared with 1.91 months for those given standard therapy.

Patients with ESR1 mutations who received 12 months or more of prior treatment with a CDK4/6 inhibitor achieved a median progression free survival of 8.61 months with elacestrant compared with 1.91 months for those given standard therapy.

Yoga has a positive impact on the vagus nerve, which influences how people think, remember, and feel, and therefore can improve the mental well-being of patients with prostate cancer.

The phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials reported that Week 24 transfusion independence resulted in an improved overall survival for patients with myelofibrosis.